An exploratory investigation of various modes of action and potential adverse outcomes of fluoxetine in marine mussels

Aquatic Toxicology

Volumn 151, Issue , 2014, Pages 14-26

  Franzellitti, Silvia ^a   Buratti, Sara ^a   Capolupo, Marco ^a   Du, Bowen ^b   Haddad, Samuel P ^b   Chambliss, C Kevin ^b   Brooks, Bryan W ^b   Fabbri, Elena ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BAYLOR UNIVERSITY   (United States)

Author keywords

Adverse outcome pathway; Biomarkers; CAMP signaling; Fluoxetine; Marine mussel; Mode of action

Indexed keywords

ACETYLCHOLINESTERASE; BIOLOGICAL MARKER; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FLUOXETINE; GLUTATHIONE TRANSFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; SEROTONIN 1 RECEPTOR; XENOBIOTIC AGENT;

BIOACCUMULATION; BIOMARKER; DETOXIFICATION; ENVIRONMENTAL STRESS; HEALTH STATUS; HYDROPHOBICITY; MEMBRANE; MOLLUSC; PROTEIN; RNA; TOXICITY;

5 HT1 GENE; ABCB GENE; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENETIC CODE; GONAD; HYDROPHOBICITY; LIPID PEROXIDATION; MARINE MAMMAL; MARKER GENE; MYTILUS GALLOPROVINCIALIS; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; TRANSCRIPTION REGULATION;

MAMMALIA; MYTILIDAE; MYTILUS GALLOPROVINCIALIS;

ADVERSE OUTCOME PATHWAY; BIOMARKERS; CAMP SIGNALING; FLUOXETINE; MARINE MUSSEL; MODE OF ACTION;

ANIMALS; AQUATIC ORGANISMS; DIGESTIVE SYSTEM; ENZYME ACTIVATION; FLUOXETINE; GENE EXPRESSION REGULATION; GILLS; HEMOCYTES; LIVER; MYTILUS; PROTEIN BINDING; WATER POLLUTANTS, CHEMICAL;

EID: 84899486169     PISSN: 0166445X     EISSN: 18791514     Source Type: Journal    
DOI: 10.1016/j.aquatox.2013.11.016     Document Type: Article

References (96)

1. Akamine Y., Yasui-Furukori N., Ieiri I., Uno T. Psychotropic drug-drug interactions involving P-glycoprotein. CNS Drugs 2012, 26:959-973.
2. Angers A., Storozhuk M.V., Duchîane T., Castellucci V.F., DesGroseillers L. Cloning and functional expression of an Aplysia 5-HT receptor negatively coupled to adenylate cyclase. J. Neurosci. 1998, 18:5586-5593.
3. Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornung M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrrano J.A., Tietge J.E., Villeneuve D.L. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29:730-741.
4. Ankley G.T., Brooks B.W., Huggett D.B., Sumpter J.P. Repeating history: pharmaceuticals in the environment. Environ. Sci. Technol. 2007, 41:8211-8217.
5. Baker D.R., Kasprzyk-Hordern B. Multi-residue determination of the sorption of illicit drugs and pharmaceuticals to wastewater suspended particulate matter using pressurised liquid extraction, solid phase extraction and liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. A 2011, 1218:7901-7913.
6. Banni M., Dondero F., Jebali J., Guerbej H., Boussetta H., Viarengo A. Assessment of heavy metal contamination using real-time PCR analysis of mussel metallothionein mt10 and mt20 expression: a validation along the Tunisian coast. Biomarkers 2007, 12:369-383.
7. Bard S.M. Multixenobiotic resistance as a cellular defence mechanism in aquatic organisms. Aquat. Toxicol. 2000, 48:357-389.
8. Berninger J.P., Brooks B.W. Leveraging mammalian pharmaceutical toxicology and pharmacology data to predict chronic fish responses to pharmaceuticals. Toxicol. Lett. 2010, 193:69-78.
9. Berninger J.P., Du B., Connors K.A., Eytcheson S.A., Kolkmeier M.A., Prosser K.N., Valenti T.W., Chambliss C.K., Brooks B.W. Effects of the antihistamine diphenhydramine to select aquatic organisms. Environ. Toxicol. Chem. 2011, 30:2065-2072.
10. Boxall A.B.A., Rudd M., Brooks B.W., Caldwell D., Choi K., Hickmann S., Innes E., Ostapyk K., Staveley J., Verslycke T., Ankley G.T., Beazley K., Belanger S., Berninger J.P., Carriquiriborde P., Coors A., DeLeo P., Dyer S., Ericson J., Gagne F., Giesy J.P., Gouin T., Hallstrom L., Karlsson M., Larsson D.G.J., Lazorchak J., Mastrocco F., McLaughlin A., McMaster M., Meyerhoff R., Moore R., Parrott J., Snape J., Murray-Smith R., Servos M., Sibley P.K., Straub J.O., Szabo N., Tetrault G., Topp E., Trudeau V.L., van Der Kraak G. Pharmaceuticals and personal care products in the environment: what are the big questions?. Environ. Health Perspect. 2012, 120:1221-1229.
11. Brausch J.M., Connors K.A., Brooks B.W., Rand G.M. Human pharmaceuticals in the aquatic environment: a critical review of recent toxicological studies and considerations for toxicity testing. Rev. Environ. Contam. Toxicol. 2012, 218:1-99.
12. Bringolf R.B., Heltsley R.M., Newton T.J., Eads C.B., Fraley S.J., Shea D., Cope W.G. Environmental occurrence and reproductive effects of the pharmaceutical fluoxetine in native freshwater mussels. Environ. Toxicol. Chem. 2010, 6:1311-1318.
13. Brooks B.W., Foran C.M., Richards S.M., Weston J., Turner P.K., Stanley J.K., Solomon K.R., Slattery M., La Point T.W. Aquatic ecotoxicology of fluoxetine. Toxicol. Lett. 2003, 142:169-183.
14. Brooks B.W., Turner P.K., Stanley J.K., Weston J., Glidewell E., Foran C.M., Slattery M., La Point T.W., Huggett D.B. Waterborne and sediment toxicity of fluoxetine to selected organisms. Chemosphere 2003, 52:135-142.
15. Brooks B.W., Berninger J.P., Ramirez A.J., Huggett D.B. Perspectives on human pharmaceuticals in the environment. Human Pharmaceuticals in the Environment: Current and Future Perspectives 2012, 1-16. Springer, New York. B.W. Brooks, D.B. Huggett (Eds.).
16. Brooks B.W., Chambliss C.K., Stanley J.K., Ramirez A.J., Banks K.E., Johnson R.D., Lewis R.J. Determination of select antidepressants in fish from an effluent-dominated stream. Environ. Toxicol. Chem. 2005, 24:464-469.
17. Brooks B.W., Huggett D.B., Boxall A.B. Pharmaceuticals and personal care products: research needs for the next decade. Environ. Toxicol. Chem. 2009, 28:2469-2472.
18. Brown N.J., Roberts L.J. Histamine, bradykinin, and their antagonists. Goodman and Gilman's Pharmacological Basis of Therapeutics 2001, 656. McGraw Hill, New York. 10th ed. J.G. Hardman, L.E. Limbird (Eds.).
19. Catterson M.L., Preskorn S.H. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol. Toxicol. 1996, 78:203-208.
20. Chu S., Metcalfe C.D. Analysis of paroxetine, fluoxetine and norfluoxetine in fish tissues using pressurized liquid extraction, mixed mode solid phase extraction cleanup and liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2007, 1163:112-118.
21. Conley J.M., Symes S.J., Schorr M.S., Richards S.M. Spatial and temporal analysis of pharmaceutical concentrations in the upper Tennessee River basin. Chemosphere 2008, 73:1178-1187.
22. Cubero-Leon E., Ciocan C.M., Hill E.M., Osada M., Kishida M., Itoh N., Kondo R., Minier C., Rotchell J.M. Estrogens disrupt serotonin receptor and cyclooxygenase mRNA expression in the gonads of mussels (Mytilus edulis). Aquat. Toxicol. 2010, 98:178-187.
23. Daniel W.A. Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27:65-73.
24. Daniel W.A., Wójcikowski J. Contribution of lyosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol. Toxicol. 1997, 80:62-68.
25. Daughton C.G., Brooks B.W. Active pharmaceuticals ingredients and aquatic organisms. Environmental Contaminants in Wildlife: Interpreting Tissue Concentrations 2011, 281-341. Taylor and Francis. 2nd ed. J. Meador, W.N. Beyer (Eds.).
26. Djordjevic J., Djordjevic A., Adzic M., Elaković I., Matić G., Radojcic M.B. Fluoxetine affects antioxidant system and promotes apoptotic signaling in Wistar rat liver. Eur. J. Pharmacol. 2011, 659:61-66.
27. Donnini F., Dinelli E., Sangiorgi F., Fabbri E. A biological and geochemical integrated approach to assess the environmental quality of a coastal lagoon (Ravenna, Italy). Environ. Int. 2007, 33:919-928.
28. Du B., Perez-Hurtado P., Brooks B.W., Chambliss C.K. Evaluation of an isotope dilution liquid chromatography tandem mass spectrometry method for pharmaceuticals in fish. J. Chromatogr. A 2012, 1253:177-183.
29. Du B., Price A.E., Scott W.C., Kristofco L.A., Ramirez A.J., Chambliss C.K., Yelderman J.C., Brooks B.W. Comparison of contaminants of emerging concern removal, discharge, and water quality hazards among centralized and on-site wastewater treatment system effluents receiving common wastewater influent. Sci. Total Environ. 2014, 466-467:976-984.
30. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
31. Ericson H., Thorsén G., Kumblad L. Physiological effects of diclofenac, ibuprofen and propranolol on Baltic Sea blue mussels. Aquat. Toxicol. 2010, 99:223-231.
32. Fabbri E., Capuzzo A. Cyclic AMP signaling in bivalve molluscs: an overview. J. Exp. Zool. A 2010, 313:179-200.
33. Fisher N.S., Teyssié J.-L., Fowler S.W., Wang W.-X. Accumulation and retention of metals in mussels from food and water: a comparison under field and laboratory conditions. Environ. Sci. Technol. 1996, 30:3232-3242.
34. Fong P.P. Zebra mussel spawning is induced in low concentrations of putative serotonin reuptake inhibitors. Biol. Bull. 1998, 194:143-149.
35. Fong P.P., Molnar N. Norfluoxetine induces spawning and parturition in estuarine and freshwater bivalves. Bull. Environ. Contam. Toxicol. 2008, 81:535-538.
36. Fong P.P., Philbert C.M., Roberts B.J. Putative serotonin reuptake inhibitor-induced spawning and parturition in freshwater bivalves is inhibited by mammalian 5-HT2 receptor antagonists. J Exp. Zool. A Comp. Exp. Biol. 2003, 298:67-72.
37. Foran C.M., Weston J.J., Slattery M., Brooks B.W., Huggett D.B. Reproductive assessment of Japanese medaka (Oryzias latipes) following a four-week fluoxetine exposure. Arch. Environ. Contam. Toxicol. 2004, 46:511-517.
38. Franzellitti S., Buratti S., Donnini F., Fabbri F. Exposure of mussels to a polluted environment: insights into the stress syndrome development. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2010, 152:24-33.
39. Franzellitti S., Buratti S., Valbonesi P., Capuzzo A., Fabbri E. The β-blocker propranolol affects cAMP-dependent signaling and induces the stress response in Mediterranean mussels, Mytilus galloprovincialis. Aquat. Toxicol. 2011, 101:299-308.
40. Franzellitti S., Fabbri E. Cyclic-AMP mediated regulation of ABCB mRNA expression in mussel haemocytes. PLoS One 2013, 8:e61634.
41. Franzellitti S., Buratti S., Valbonesi P., Fabbri E. The mode of action (MOA) approach reveals interactive effects of environmental pharmaceuticals on Mytilus galloprovincialis. Aquat. Toxicol. 2013, 140-141:249-256.
42. Gonzalez-Rey M., Bebianno M.J. Does selective serotonin reuptake inhibitor (SSRI) fluoxetine affects mussel Mytilus galloprovincialis?. Environ. Pollut. 2013, 173:200-209.
43. Gorbi S., Bocchetti R., Binelli A., Bacchiocchi S., Orletti R., Nanetti L., Raffaelli F., Vignini A., Accoroni S., Totti C., Regoli F. Biological effects of palytoxin-like compounds from Ostreopsis cf. ovata: a multibiomarkers approach with mussels Mytilus galloprovincialis. Chemosphere 2012, 89:623-632.
44. Gros M., Petrović M., Barceló D. Development of a multi-residue analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters. Talanta 2006, 70:678-690.
45. Gunnarsson L., Jauhiainen A., Kristiansson E., Nerman O., Larsson D.G.J. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environ. Sci. Technol. 2008, 42:5807-5813.
46. Hannon J., Hoyer D. Molecular biology of 5-HT receptors. Behav. Brain Res. 2008, 195:198-213.
47. Hazelton P.D., Cope W.G., Mosher S., Pandolfo T.J., Belden J.B., Barnhart M.C., Bringolf R.B. Fluoxetine alters adult freshwater mussel behavior and larval metamorphosis. Sci. Total Environ. 2013, 445-446:94-100.
48. Huggett D.B., Cook J.C., Ericson J.F., Williams R.T. A theoretical model for utilizing mammalian pharmacology and safety data to prioritize potential impacts of human pharmaceuticals to fish. Hum. Ecol. Risk Assess. 2003, 9:1789-1799.
49. Klosterhaus S.L., Grace R., Hamilton M.C., Yee D. Method validation and reconnaissance of pharmaceuticals, personal care products, and alkylphenols in surface waters, sediments, and mussels in an urban estuary. Environ Int. 2013, 54:92-99.
50. Kolpin D.W., Furlong E.T., Meyer M.T. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ. Sci. Technol. 2002, 36:1202-1211.
51. Kreke N., Dietrich D.R. Physiological endpoints for potential SSRI interactions in fish. Critical Rev. Toxicol. 2008, 37:215-247.
52. Kwon J.-W., Armbrust K.L. Laboratory persistence and fate of fluoxetine in aquatic environments. Environ. Toxicol. Chem. 2006, 25:2561-2568.
53. Lazzara R., Blázquez M., Porte C., Barata C. Low environmental levels of fluoxetine induce spawning and changes in endogenous estradiol levels in the zebra mussel Dreissena polymorpha. Aquat. Toxicol. 2012, 106-107:123-130.
54. Livak K.J., Schmittgen T.D. Analyzing real-time PCR data by the comparative CT method. Nature Protoc. 2008, 3:1101-1108.
55. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
56. Martin-Diaz M.L., Franzellitti S., Buratti S., Valbonesi P., Capuzzo A., Fabbri E. Effects of environmental concentrations of the antiepileptic drug carbamazepine on biomarkers and cAMP-mediated cell signaling in the mussel Mytilus galloprovincialis. Aquat. Toxicol. 2009, 94:177-185.
57. Martinez-Gomez C., Benedicto J., Campillo J.A., Moore M. Application and evaluation of the neutral red retention (NRR) assay for lysosomal stability in mussel populations along the Iberian Mediterranean coast. J. Environ. Monit. 2008, 10:490-499.
58. Meredith-Williams M., Carter L.J., Fussell R., Raffaelli D., Ashauer R., Boxall A.B.A. Uptake and depuration of pharmaceuticals in aquatic invertebrates. Environ. Pollut. 2012, 165:250-258.
59. Metcalfe C.D., Miao X.-S., Koenig B.G., Struger J. Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. Environ. Toxicol. Chem. 2003, 22:2881-2889.
60. Mimeault C., Trudeau V.L., Moon T.W. Waterborne gemfifrozil challenges the hepatic antioxidant defense system and down-regulates peroxisome proliferator-activated receptor beta (PPARbeta) mRNA levels in male goldfish (Carassius auratus). Toxicology 2006, 228:140-150.
61. Minier C., Borghi V., Moore M.N., Porte C. Seasonal variation of MXR and stress proteins in the common mussel, Mytilus galloprovincialis. Aquat. Toxicol. 2000, 50:167-176.
62. Moore M.N. Cytochemical demonstration of latency of lysosomal hydrolases in digestive gland cells of the common mussel Mytilus edulis, and changes induced by thermal stress. Cell Tissue Res. 1976, 175:279-287.
63. Moore M.N. Diet restriction induced autophagy: a lysosomal protective system against oxidative- and pollutant-stress and cell injury. Mar. Environ. Res. 2004, 58:603-607.
64. Moore M.N., Allen J.I., McVeigh A., Shaw J. Lysosomal and autophagic reactions as predictive indicators of environmental impact in aquatic animals. Autophagy 2006, 2:217-220.
65. Moore M.N., Clarke K.R. Use of microstereology and cytochemical staining to determine the effects of crude oil-derived aromatic hydrocarbons on lysosomal structure and function in a marine bivalve mollusc Mytilus edulis. Histochem. J. 1982, 14:713-718.
66. Moore M.N., Viarengo A., Donkin P., Hawkins A.J. Autophagic and lysosomal reactions to stress in the hepatopancreas of blue mussels. Aquat. Toxicol. 2007, 84:80-91.
67. Müller T.C., Rocha J.B., Morsch V.M., Neis R.T., Schetinger M.R. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. Biochim. Biophys. Acta 2002, 1587:92-98.
68. Nakamura Y., Yamamoto H., Sekizawa J., Kondo T., Hirai N., Tatarazako N. The effects of pH on fluoxetine in Japanese medaka (Oryzias latipes): acute toxicity in fish larvae and bioaccumulation in juvenile fish. Chemosphere 2008, 70:865-873.
69. Oakes K.D., Coors A., Escher B.I., Fenner K., Garric J., Gust M., Knacker T., Küster A., Kussatz C., Metcalfe C.D., Monteiro S., Moon T.W., Mennigen J.A., Parrott J., Péry A.R., Ramil M., Roennefahrt I., Tarazona J.V., Sánchez-Argüello P., Ternes T.A., Trudeau V.L., Boucard T., Van Der Kraak G.J., Servos M.R. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: case study using the European risk assessment framework. Integr. Environ. Assess. Manage. 2010, 6:524-539.
70. Overmyer J.P., Smith P.F., Kellock K.A., Kwon J.-W., Armbrust K. Assessment of the toxicological interaction of sertraline with cholinesterase inhibiting insecticides in aquatic insects using the black fly, Simulium vittatum IS-7. Environ. Toxicol. 2010, 25:28-37.
71. Park J.W., Heah T.P., Gouffon J.S., Henry T.B., Sayler G.S. Global gene expression in larval zebrafish (Danio rerio) exposed to selective serotonin reuptake inhibitors (fluoxetine and sertraline) reveals unique expression profiles and potential biomarkers of exposure. Environ. Pollut. 2012, 167:163-170.
72. Peroutka S.J. 5-Hydroxytryptamine receptors in vertebrates and invertebrates: why is there so many?. Neurochem. Int. 1994, 25:533-536.
73. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30:e36.
74. Ram J.L., Fong P.P., Garton D.W. Physiological aspects of zebra mussel reproduction: maturation, spawning, and fertilization. Am. Zool. 1996, 36:326-338.
75. Ramirez A.J., Mottaleb M.A., Brooks B.W., Chambliss C.K. Analysis of pharmaceuticals in fish using liquid chromatography-tandem mass spectrometry. Anal. Chem. 2007, 79:3155-3163.
76. Ramirez A.J., Brain R.A., Usenko S., Mottaleb M.A., O'Donnell J.G., Stahl L.L., Wathen J.B., Snyder B.D., Pitt J.L., Perez-Hurtado P., Dobbins L.L., Brooks B.W., Chambliss C.K. Occurrence of pharmaceuticals and personal care products in fish: results of a national pilot study in the United States. Environ. Toxicol. Chem. 2009, 28:2587-2597.
77. Regoli F., Giuliani M.E. Oxidative pathways of chemical toxicity and oxidative stress biomarkers in marine organisms. Mar. Environ. Res. 2013, 1136(13):121-129. 10.1016/j.marenvres.2013.07.006.
78. Schmitt H., Boucard T., Garric J., Jensen J., Parrott J., Péry A., Römbke J., Straub J.-O., Hutchinson T.H., Sánchez-Argüello P., Wennmalm A., Duis K. Recommendations on the environmental risk assessment of pharmaceuticals: effect characterization. Integr. Environ. Assess. Manage. 2010, 6:S588-S602.
79. Seiler J.P. Pharmacodynamic activity of drugs and ecotoxicology-can the two be connected?. Toxicol. Lett. 2002, 131:105-115.
80. Stanley J.K., Ramirez A.J., Chambliss C.K., Brooks B.W. Enantiospecific sublethal effects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate. Chemosphere 2007, 69:9-16.
81. Tierney A.J. Structure and function of invertebrate 5-HT receptors: a review. Comp. Biochem. Physiol. A 2001, 128:791-804.
82. Tiu S.H., He J.G., Chan S.M. Organization and expression study of the shrimp (Metapenaeus ensis) putative 5-HT receptor: up-regulation in the brain by 5-HT. Gene 2005, 353:41-52.
83. UNEP/RAMOGE, 1999. Manual on Biomarkers Recommended for the MED POL Biomonitoring Programme. UNEP, Athens, 39 pp.
84. Valbonesi P., Caselli F., Capuzzo A., Fabbri E. Modulation of adenyl cyclase activity in the gills of Tapes philippinarum. J. Exp. Zool. A 2004, 301:952-960.
85. Valbonesi P., Sartor G., Fabbri E. Characterization of cholinesterase activity in three bivalves inhabiting the North Adriatic sea and their possible use as sentinel organisms for biosurveillance programmes. Sci. Total Environ. 2003, 312:79-88.
86. Valenti T.V., Gould G.G., Berninger J.P., Connors K.A., Keele N.B., Prosser K.N., Brooks B.W. Human therapeutic plasma levels of the selective serotonin reuptake inhibitor (SSRI) sertraline decrease serotonin reuptake transporter binding and shelter seeking behavior in adult male fathead minnows. Environ. Sci. Technol. 2012, 46:2427-2435.
87. Valenti T.W., Perez-Hurtado P., Chambliss C.K., Brooks B.W. Aquatic toxicity of sertraline to Pimephales promelas at environmentally relevant surface water pH. Environ. Toxicol. Chem. 2009, 28:2685-2694.
88. Vanderford B.J., Snyder S.A. Analysis of pharmaceuticals in water by isotope dilution liquid chromatography/tandem mass spectrometry. Environ. Sci. Technol. 2006, 40:7312-7320.
89. van der Ven K., Keil D., Moens L.N., van Leemput K., van Remortel P., de Coen W.M. Neuropharmaceuticals in the environment: mianserin- induced neuroendocrine disruption in zebrafish (Danio rerio) using cDNA microarrays. Environ. Toxicol. Chem. 2006, 25:2645-2652.
90. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. 00341-0034.
91. Vasskog T., Anderssen T., Pedersen-Bjergaard S., Kallenborn R., Jensen E. Occurrence of selective serotonin reuptake inhibitors in sewage and receiving waters at Spitsbergen and in Norway. J. Chromatogr. A 2008, 1185:194-205.
92. Veith G.D., Defoe D.L., Bergstedt B.V. Measuring and estimating the bioconcentration factor of chemicals on fish. J. Fish Res. Board Can. 1979, 36:1040-1048.
93. Viarengo A., Lowe D., Bolognesi C., Fabbri E., Koehler A. The use of biomarkers in biomonitoring: a 2-tier approach assessing the level of pollutant-induced stress syndrome in sentinel organisms. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2007, 146:281-300.
94. Vidal-Liñán L., Bellas J. Practical procedures for selected biomarkers in mussels, Mytilus galloprovincialis - Implications for marine pollution monitoring. Sci. Total Environ. 2013, 461-462C:56-64.
95. WHO, 2012. Pharmaceuticals in drinking-water. WHO Technical Reports, Geneva, Switzerland, pp. 52.
96. Wong D.T., Perry K.W., Bymaster F.P. The discovery of fluoxetine hydrochloride (Prozac). Nature Rev. Drug Discov. 2005, 4:764-774.